These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30597973)

  • 1. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
    Ueno SI; Saiki S; Fujimaki M; Takeshige-Amano H; Hatano T; Oyama G; Ishikawa KI; Yamaguchi A; Nojiri S; Akamatsu W; Hattori N
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.
    Saiki S; Hatano T; Fujimaki M; Ishikawa KI; Mori A; Oji Y; Okuzumi A; Fukuhara T; Koinuma T; Imamichi Y; Nagumo M; Furuya N; Nojiri S; Amo T; Yamashiro K; Hattori N
    Sci Rep; 2017 Aug; 7(1):7328. PubMed ID: 28779141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
    Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
    J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.
    Cova I; Di Battista ME; Vanacore N; Papi CP; Alampi G; Rubino A; Valente M; Meco G; Contri P; Di Pucchio A; Lacorte E; Priori A; Mariani C; Pomati S
    Parkinsonism Relat Disord; 2017 Jan; 34():38-42. PubMed ID: 28029554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyneuropathy in levodopa-treated Parkinson's patients.
    Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
    J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?
    De Luka SR; Svetel M; Pekmezović T; Milovanović B; Kostić VS
    Vojnosanit Pregl; 2014 Apr; 71(4):346-51. PubMed ID: 24783414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
    Jankovic J; Hunter C
    Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
    Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
    Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Parkinson's disease and levodopa on adaptation of anticipatory postural adjustments.
    Hall LM; Brauer SG; Horak F; Hodges PW
    Neuroscience; 2013 Oct; 250():483-92. PubMed ID: 23867768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
    Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N
    BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.